1.646.889.1200|info@lifescipublicrelations.com

Reata’s bardoxolone hits goals in phase 2 kidney disease trial

//Reata’s bardoxolone hits goals in phase 2 kidney disease trial

Reata’s bardoxolone hits goals in phase 2 kidney disease trial

Reata Pharmaceuticals’ bardoxolone has improved kidney function in patients with IgA nephropathy and type 1 diabetic chronic kidney disease (CKD). The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate (eGFR), a measure of kidney damage.

By | 2018-09-25T10:54:23-04:00 September 25th, 2018|News|Comments Off on Reata’s bardoxolone hits goals in phase 2 kidney disease trial

About the Author:

Related Posts

LifeSci Public Relations

LifeSci Public Relations LLC is a corporate communications and public relations firm helping clients engage their corporate audiences and achieve their business objectives via a broad array of traditional, social and digital media tools.